Legends to figures
Figure 1: the PlGF levels among cases with PE (A) and severe PE (B) compared to normal outcome
Figure 2: ROC curve of PlGF estimation at gestational age of 20-22, 28-30, 34-36 weeks of gestation
Figure 3: The bar diagram showing the comparison of factors deranged LFT, severe high blood pressure more than 150/100 mmHg, FGR, sFLT-1/PlGF ratio above cut-off along with PlGF below cut-off
References
  1. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018; 72:24–43.
  2. Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017 Dec;31(12):782-786. doi: 10.1038/jhh.2017.61. Epub 2017 Aug 24. PMID: 29115294; PMCID: PMC5680413.
  3. Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017 Oct;50(4):492-495. doi: 10.1002/uog.18816. Epub 2017 Aug 24.
  4. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D’Alton M, Berghella V, Nicolaides KH, Hod M. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019 May;145 Suppl 1(Suppl 1):1-33.
  5. Heimberger S, Mueller A, Ratnaparkhi R, Perdigao JL, Rana S. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. Pregnancy Hypertens. 2020 Apr;20:124-130.
  6. Kumar M, Balyan K, Debnath E, Shankar S, Apte A, Jha S. Role of sFLT-1/PlGF ratio in predicting severe adverse materno-fetal outcome in high risk women. Pregnancy Hypertens. 2022 Dec;30:154-160.
  7. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press, 2010.
  8. Papageorghiou AT, Kennedy SH, Salomon LJ, Altman DG, Ohuma EO, Stones W, Gravett MG, Barros FC, Victora C, Purwar M, Jaffer Y, Noble JA, Bertino E, Pang R, Cheikh Ismail L, Lambert A, Bhutta ZA, Villar J; International Fetal and Newborn Growth Consortium for the 21(st) Century (INTERGROWTH-21(st)). The INTERGROWTH-21st fetal growth standards:toward the global integration of pregnancy and pediatric care. Am J Obstet Gynecol. 2018 Feb;218(2S):S630-S640. doi: 10.1016/j.ajog.2018.01.011.
  9. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, Silver RM, Wynia K, Ganzevoort W. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;3(48):333–339.
  10. Mclaughlin PlGF (Placental Growth Factor) Testing in Clinical Practice Evidence From a Canadian Tertiary Maternity Referral Center Kelsey McLaughlin , John W. Snelgrove , Melanie C. Audette , Atif Syed, Sebastian R. Hobson, Rory C. Windrim, Nir MelamedDuhig at, Sergio Carmona, John C. Kingdom
  11. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan AH, Chappell LC; PARROT trial group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019 May 4;393(10183):1807-1818. doi: 10.1016/S0140-6736(18)33212-4
  12. Ormesher L, Johnstone ED, Shawkat E, et al. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction. Pregnancy Hypertens 2018; 14: 234–39.
  13. Lim, Sean; Li, Wentao MD, PhD; Kemper, Jessica; Nguyen, Andrew; Mol, Ben Willem MD, FRANZCOG; Reddy, Maya MBBS, BMedSc. Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. Obstetrics & Gynecology 137(1):p 72-81, January 2021.
  14. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128:2121–31.
  15. Sharp A, Chappell LC, Dekker G, et al. Placental growth factor informed management of suspected pre-eclampsia or fetal growth restriction: the MAPPLE cohort study. Pregnancy Hypertens 2018;14: 228–33.
  16. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–9.
  17. Duckworth S, Chappell LC, Seed PT, Mackillop L, Shennan AH, Hunter R. Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia Prior to 35 Weeks’ Gestation: A Budget Impact Analysis. PLoS One. 2016 Oct 14;11(10):e0164276.
  18. Stepan H, Hund M, Andraczek T. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome. Hypertension. 2020 Apr;75(4):918-926.